MedTrace Logo

Non-Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population

NCT02012972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 354

Last updated 2021-01-08

No results posted yet for this study

Summary

For national antiretroviral therapy (ART) programs, the most important health system goals in reducing morbidity and mortality among HIV-infection patients are to initiate treatment as early as eligibility criteria allow and to achieve the highest possible long-term retention of patients on ART. In South Africa, cohort data have consistently found high attrition among ART patients, with the combined cumulative outcomes of death and loss to follow up averaging 25-40% over the first five years after ART initiation. Like many other middle income countries, South Africa also faces very high rates of non-communicable diseases (NCDs) and NCD risks. Despite this, there are virtually no studies looking at interactions between ART and NCDs, and none that have considered the effect of NCDs and NCD risk factors on achieving the second health system goal mentioned above: long term retention on ART.

Conditions

Interventions

BEHAVIORAL

Referral for NCD care

Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.

Sponsors & Collaborators

  • University of Witwatersrand, South Africa

    collaborator OTHER

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • City of Johannesburg

    collaborator UNKNOWN

  • Boston University

    lead OTHER

Principal Investigators

  • Sydney Rosen, MPA · Boston University

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02012972 on ClinicalTrials.gov